企業プロフィール
Delcath Systems 株価・ニュース・カタリスト
- ティッカー:
- DCTH
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
17.05 USD (+1.91%)
終値
最終更新: 2026年8月17日
364M USD
時価総額
株価変動の要因
As of Aug 17, 2026, DCTH closed up 1.91% at $17.05. No new same-company headline was identified in the current news window.
企業概要
Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training and procedure-based consumable sales.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。